Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds

International Journal of Infectious Diseases

Volumn 14, Issue 1, 2010, Pages

  Palacios, Gerardo C ^a   Sanchez, Luz M ^a   Briones, Evangelina ^b   Ramirez, Teresa J ^c   Castillo, Hugo ^c   Rivera, Lydia G ^d   Vazquez, Carlos A ^a   Rodriguez Padilla, Cristina ^d   Holodniy, Mark ^e  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c SECRETARÍA DE SALUD   (Mexico)

^d Laboratorio de Inmunologia y Virologia   (Mexico)

^e NONE

Author keywords

Acquired immunodeficiency syndrome (AIDS); Highly active antiretroviral therapy (HAART); Structured treatment interruptions

Indexed keywords

INDINAVIR; LAMIVUDINE; RITONAVIR; ZALCITABINE; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CLINICAL TRIAL; DRUG SUBSTITUTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; REBOUND; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE COUNT; MALE; TREATMENT OUTCOME; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 74949096947     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.03.003     Document Type: Article

References (37)

1. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. February 28, 2008. Available at: http://aidsinfo.nih.gov/contentfiles/PediatricGuidelines (accessed March 2008).
2. Sánchez-Granados J.M., Ramos-Amador J.T., Fernández-de-Miguel S., González-Tomée M.I., Rojo-Conejo P., Vivas P.F., et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J 22 (2003) 863-867
3. Palacios G.C., Palafox V.L., Alvarez M.T., Vazquez G., Miranda G., Muñoz O., et al. Response to two consecutive protease inhibitor combination therapy regimens in a cohort of HIV-1 infected children. Scand J Infect Dis 34 (2002) 41-44
4. Sáez-Llorens X., and Ramilo O. Early experience with protease inhibitors in human immunodeficiency virus-infected children. Pediatr Infect Dis J 17 (1998) 728-738
5. Solórzano-Santos F., Gochicoa-Rangel L.G., Palacios-Saucedo G., Vázquez-Rosales G., and Miranda-Novales M.G. Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-infected children treated with protease inhibitors. Arch Med Res 37 (2006) 129-132
6. Plebani A., Esposito S., Pinzani R., Fesslova V., Bojanin J., Salice P., et al. Effect of highly active antiretroviral therapy on cardiovascular involvement in children with human immunodeficiency virus infection. Pediatr Infect Dis J 23 (2004) 559-563
7. Opravil M., Baumann D., Chave J.P., Furrer H., Calmy A., Bernasconi E., et al. Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. AIDS 18 (2004) 2213-2215
8. Deeks S.G., Wrin T., Liegler T., Hoh R., Hayden M., Barbour J.D., et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344 (2001) 472-480
9. Lori F., and Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA 286 (2001) 2981-2987
10. Fagard C., Oxenius A., Günthard H., Garcia F., Le Braz M., Mestre G., et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 163 (2003) 1220-1226
11. Yerly S., Günthard H.F., Fagard C., Joos B., Perneger T.V., Hirschel B., et al. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 18 (2004) 1951-1953
12. Lori F., Maserati R., Foli A., Seminari E., Timpone J., and Lisziewicz J. Structured treatment interruptions to control HIV. Lancet 355 (2000) 287-288
13. Miller V., Sabin C., Hertogs K., Bloor S., Martinez-Picado J., D'Aquila R., et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14 (2000) 2857-2867
14. Lori F., Lewis M.G., Xu J., Varga G., Zinn D.E., Crabbs C., et al. Control of HIV rebound through structured treatment interruptions during early infection. Science 290 (2000) 1591-1593
15. Giard M., Boibieux A., Ponceau B., Biron F., Braun E., Issartel B., et al. Treatment interruption in HIV infected patients: clinical and biological evolution. Med Malad Infect 35 (2005) 525-529
16. Gibb D.M., Duong T., Leclezio V.A., Walker A.S., Verweel G., and Dunn D.T. Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 23 (2004) 446-450
17. Borkowsky W., Yogev R., Muresan P., McFarland E., Frenkel L., Fenton T., et al. Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremia. AIDS Res Hum Retroviruses 24 (2008) 401-411
18. Centers for Disease Control and Prevention (CDC). 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep 1994; 43(RR-12):1-10.
19. In: Lang T., and Secic M. (Eds). How to report statistics in medicine Annotated guidelines for authors and reviewers (1997), American College of Physicians series, Philadelphia
20. nd ed. México: Secretaría de Salud; 2005-2006. Available at: http://www.salud.gob.mx/conasida (accessed April 2009).
21. Marchou B., Tangre P., Charreau I., Izopet J., Girard P.M., May T., et al. Intermittent antiretroviral therapy in patients with controlled HIV infection. AIDS 21 (2007) 457-466
22. Bongiovanni M., Casana M., Tincati C., and d'Arminio Monforte A. Treatment interruptions in HIV-infected subjects. J Antimicrob Chemother 58 (2006) 502-505
23. Julg B., and Goebel F.D. Treatment interruption in HIV therapy: a SMART strategy?. Infection 34 (2006) 186-188
24. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
25. Sanchez R., Portilla J., Gimeno A., Boix V., Llopis C., Sanchez-Paya J., et al. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment. J Infect 54 (2007) 159-166
26. Pai N.P., Tulsky J.P., Lawrence J., Colford J.M., and Reingold A.L. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev 4 (2005) CD005482
27. Arnedo-Valero M., Garcia F., Gil C., Gvila T., Fumero E., Castro P., et al. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Infect Dis 41 (2005) 883-890
28. Ortiz G.M., Wellons M., Brancato J., Vo H.T., Zinn R.L., Clarkson D.E., et al. Structured antiretroviral treatment interruptions in chronically HIV-1infected subjects. Proc Natl Acad Sci USA 98 (2001) pp. 13288-93
29. Currier J.S., and Baden L.R. Getting smarter The toxicity of undertreated HIV infection. N Engl J Med 355 (2006) 2359-2361
30. Gibb DM, Compagnucci A, Green H, Lallemant M, Saidi Y, Ngo-Giang-Huong N, et al. Treatment interruption in children with chronic HIV-infection: the results of the Paediatric European Network for Treatment of AIDS (PENTA) 11 trial. 9th International Congress on Drug Therapy in HIV infection. Glasgow, Scotland. November 9-13, 2008. J Intern AIDS Soc 2008; 11(Suppl 1):O21.
31. Diallo K., Götte M., and Wainberg M.A. Molecular impact of the M184 V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 47 (2003) 3377-3383
32. Trivedi V., Von Lindern J., Montes-Walters M., Rojo D.R., Shell E.J., Parkin N., et al. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility. AIDS Res Hum Retroviruses 24 (2008) 1291-1300
33. Shearer W.T., Quinn T.C., LaRussa P., Lew J.F., Mofenson L., Almy S., et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1 Women and Infants Transmission Study Group. N Engl J Med 336 (1997) 1337-1342
34. McIntosh K., Shevitz A., Zaknun D., Kornegay J., Chatis P., Karthas N., et al. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J 15 (1996) 1087-1091
35. Bartlett J.A., DeMasi R., Dawson D., and Hill A. Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. J Infect Dis 178 (1998) 1803-1805
36. Hughes M.D., Johnson V.A., Hirsch M.M.S., Bremer M.J.W., Elbeik T., Erice A., et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 126 (1997) 929-938
37. Kilby J.M., Goepfert P.A., Miller A.P., Gnann J.W., Sillers M., Saag M.S., et al. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: a case report. Ann Intern Med 133 (2000) 435-438